No profile data available.
Lyra Therapeutics, Inc. (LYRA) is a healthcare company in the additional breathing treatment drugs industry, based in Watertown, United States, with about 27 full-time employees.
It reported revenue of $1.53 million for fiscal year 2024, down 1.9% from fiscal year 2023, and net income of -$93.44 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $25,000. Its market capitalization was $337,227 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Lyra Therapeutics reported $1.53 million in revenue for fiscal year 2024, down 1.9% from $1.56 million in fiscal year 2023. In Q3 2025 revenue was $25,000.
$337,227 as of October 9, 2026.
Listed companies of a similar size in the same industry (additional breathing treatment drugs) include Connect Biopharma Holdings Limited (CNTB).